Screener
ARS Pharmaceuticals, Inc. SPRY Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026.
- Filed
- May 15, 2026, 6:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225142
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Prepaid expenses and other assets | (524) | (4,796) |
| Accounts payable and accrued liabilities | 10,315 | 4,168 |
| Contract liability | (61) | (210) |
| Net cash and cash equivalents used in operating activities | (44,946) | (40,742) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments, available-for-sale | (14,709) | (34,345) |
| Maturities of short-term investments, available-for-sale | 42,500 | 63,500 |
| Purchases of property and equipment | — | (91) |
Item 1. Financial Statements
FAQ
- What is ARS Pharmaceuticals, Inc.'s operating cash flow?
- ARS Pharmaceuticals, Inc. (SPRY) reported operating cash flow of -$44.95M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s operating cash flow changed year-over-year?
- ARS Pharmaceuticals, Inc.'s operating cash flow decreased by 10.3% year-over-year, from -$40.74M to -$44.95M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s operating cash flow?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s operating cash flow has grown at a 62.1% compound annual growth rate (CAGR), from -$40.08M to -$170.87M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about ARS Pharmaceuticals, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude